NASDAQ: ABVC - ABVC BioPharma, Inc.

Rentabilidad a seis meses: -3.24%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción ABVC BioPharma, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

más detalles
The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2017-10-11
ISIN US00091F1066
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.abvcpharma.com
Цена ао 0.688
Cambio de precio por día: +0.0155% (0.6459)
Cambio de precio por semana.: +2.15% (0.6324)
Cambio de precio por mes: +54.18% (0.419)
Cambio de precio en 3 meses.: +26.67% (0.51)
Cambio de precio en seis meses: -3.24% (0.6676)
Cambio de precio por año: -44.31% (1.16)
Cambio de precio en 3 años.: -71.67% (2.28)
Cambio de precio en 5 años.: -89.58% (6.2)
Cambio de precio en 10 años.: +0% (0.646)
Cambio de precio desde principios de año.: +9.36% (0.5907)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 34.42 1
P/BV 0.6113 10
P/E 0 0
EV/EBITDA -0.8525 0
Total: 4.25

Eficiencia

Nombre Significado Calificación
ROA, % -70.37 0
ROE, % -118.96 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.2994 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % -78.29 0
Rentabilidad Ebitda, % 146.44 10
Rentabilidad EPS, % 7.8 1
Total: 5.2
Más detalles

Instituciones Volumen Compartir, %
Renaissance Technologies, LLC 36100 0.34
Vanguard Group Inc 27247 0.26
Citadel Advisors Llc 27158 0.26
Geode Capital Management, LLC 19480 0.18
Tower Research Capital LLC (TRC) 578 0.01
Spotlight Asset Group, Inc. 100 0
Royal Bank of Canada 37 0
Wells Fargo & Company 20 0



Supervisor Título profesional Pago año de nacimiento
Mr. Eugene Jiang Chairman & Chief Business Officer 200k 1986 (39 años)
Dr. Tsung-Shann Jiang EMBA, Ph.D. Chief Scientific Officer, Chief Strategy Officer & Director 200k 1954 (71 año)
Dr. Uttam Yashwant Patil Ph.D. CEO & Interim CFO N/A 1986 (39 años)

DIRECCIÓN: United States, Fremont. CA, 44370 Old Warm Springs Boulevard - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.abvcpharma.com